Apellis Pharmaceuticals (APLS) stock gains as Bank of America upgrades the firm, citing a strong commercial rollout of its ...
Sweden’s Sobi has announced that the European Commission (EC) has approved Aspaveli (pegcetacoplan) for adults and ...
How would you treat a 30-year-old woman with systemic lupus erythematous (SLE) and lupus nephritis (LN) class 3 with new ...
Sobi® (STO: SOBI), today announced that the European Commission (EC) has approved Aspaveli® (pegcetacoplan) for the treatment of adult and adolescent patients aged 12 to 17 years with C3 ...
Not intended for the UK Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, ...
European Commission approves Sobi’s Aspaveli for the treatment of C3G and primary IC-MPGN: Stockholm Monday, January 19, 2026, 10:00 Hrs [IST] Sobi, a global biopharma company u ...
Verywell Health on MSN
Types of complement 3 glomerulopathy: How they differ and what that means
Medically reviewed by Erika Prouty, PharmD Key Takeaways There are two types of complement 3 glomerulopathy: dense deposit ...
Medically reviewed by Femi Aremu, PharmD Complement 3 glomerulopathy (C3G) is a rare type of kidney disease. There are two types: C3 glomerulonephritis (C3GN) and dense deposit disease (DDD).C3GN is ...
Not intended for the UK Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, targeted, non-immunosuppressive therapy in people with prima ...
Zacks.com on MSN
Apellis Stock Crashes 23% in a Week: Here's What You Should Know
Shares of Apellis Pharmaceuticals APLS have crashed 22.6% in the past week. The massive stock price decline was observed ...
Approximately 8,000 people in Europe are living with C3G or primary IC-MPGN Aspaveli (pegcetacoplan) is the first treatment of primary IC-MPGN and the first treatment for C3G and primary IC-MPGN ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results